TRIlogy-3

A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Near Add Your Location

Sorting 42 by

  • Accepting patients
  • Accepting patients
  • Accepting patients
  • Accepting patients
Massachusetts General Hospital
Charlestown HealthCare Center
Charlestown, MA
  • Accepting patients
  • Accepting patients
  • Accepting patients
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.